Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
16 Maio 2022 - 05:05PM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces a delay in the
filing of its Quarterly Report on Form 10-Q for the three months
ended March 31, 2022. The delay is related to the ongoing
accounting review of Biocept’s financial statements as of and for
the three months ended March 31, 2022, which ongoing review is a
result of a change in circumstances at the U.S. Health Resources
Services Administration (HRSA) and the resulting impact on its
funding for reimbursement for COVID-19 testing services, including
those performed by Biocept.
Biocept expects to file its Form 10-Q on or before May 23, 2022.
The company intends to issue a press release announcing financial
results for the three months ended March 31, 2022 along with the
filing of the Form 10-Q, and in that press release intends to
provide a date and time for an investment community conference call
to discuss first quarter 2022 financial results as well as the
company’s business strategy.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes cerebrospinal fluid
tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "expect" and "intend" or the negative of
these words or other variations on these words or comparable
terminology. To the extent that statements in this news release are
not strictly historical, including, without limitation, statements
relating to the expected timing of our Form 10-Q filing, the timing
and content of our press release announcing financial results for
the three months ended March 31, 2022, the timing and content of
our investment community conference call, and our ability to
provide physicians with clinically actionable information for
treating and monitoring patients diagnosed with a variety of
cancers, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors, including the risk that we
may discover additional accounting issues which require additional
review time, the potential loss of key members of our management
team, resource constraints and our products and services may not
perform as expected. These and other risks are described in greater
detail under the “Risk Factors” heading of our Annual Report on
Form 10-K for the fiscal year ended December 31, 2021, as filed
with the Securities and Exchange Commission on April 5, 2022. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this news release. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to
update the information contained in this press release except as
required by law. Readers are advised to review our filings with the
SEC at http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220516005973/en/
Investor and Media Contact: Jody Cain, LHA Investor
Relations Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024